Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Cadrenal Therapeutics Inc
CVKD
Healthcare
Biotechnology
Cadrenal Therapeutics, Inc. is a biopharmaceutical company. The Company is developing tecarfarin for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions. Tecarfarin has orphan drug and fast track designations from...
the United States Food and Drug Administration for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage kidney disease (ESKD) and atrial fibrillation (AFib). It is also pursuing additional regulatory strategies for unmet needs in anticoagulation therapy for patients with left ventricular assist devices (LVADs) and those with thrombotic antiphospholipid syndrome (APS). Tecarfarin is specifically designed to leverage a different metabolism pathway than the commonly prescribed Vitamin K Antagonist (warfarin).
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:CVKD)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
Next
(0)
•••
PressRelease
X
Post by
PressRelease
on Sep 23, 2024 4:15pm
New Press Release - Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference
PONTE VEDRA, Fla., Sept. 23, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed to be a superior and safer chronic anticoagulant for warfarin-dependent patients with implanted...
read article.
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Sep 13, 2024 11:20am
CVKD.....My take ....FWIW
This up-coming meeting with FDA could prov to be a major catalyst Caution is needed This has to hold ~ $9.20 or I will say somebody knows something ...no conspiracy here I'm sure I'm wrong
...more
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Sep 13, 2024 11:14am
CVKD....LoL my timing is impeccable....R u watching the dip?
now at $10.05 and Green to Red move Cheers !
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Sep 13, 2024 10:26am
CVKD,,,,$12.00 Holla !!!!
Low volume runner.....I'm out ; ) Sold to America
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Sep 13, 2024 9:48am
CVKD......I call this daily action "Walkin the Dog"
Now over $11 which is the highest price since the recent Reverse Split....just sayin Up coming meeting with FDA
(0)
•••
PressRelease
X
Post by
PressRelease
on Sep 11, 2024 1:03pm
New Press Release - Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing
NEW YORK, NY / ACCESSWIRE / September 11, 2024 / Investor Summit Group, an independent organization focused on creating networking opportunities for the MicroCap and SmallCap community, has announced that presentations from the August 20 Microcap Investor Summit Virtual 2024 Conference are now...
read article.
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Aug 22, 2024 10:00am
Type B FDA Meeting....FYI
What are Type B FDA meetings?
...more
(72)
•••
Iseneschal
X
Comment by
Iseneschal
on Aug 22, 2024 9:15am
RE:CVKD....I hope u all realize this is going to rip to......
Read the previous post which has the todays News Release. Cheers !
(0)
•••
PressRelease
X
Post by
PressRelease
on Aug 22, 2024 9:01am
New Press Release - Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients
PONTE VEDRA, Fla., Aug. 22, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, next-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes...
read article.
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Aug 20, 2024 2:27pm
CVKD......I am now waiting for "The Dip"
Low volume will get this nowhere ; ) Pick your spot....currently trading at $6.87 Cheers !
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Aug 20, 2024 2:11pm
CVKD....I hope u all realize this is going to rip to......
Double digits.....JMHO Cheers !
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Aug 20, 2024 2:06pm
CVKD....here we go Packers here we Go!!!!
$8 holla
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Aug 20, 2024 1:49pm
CVKD....Halted on mini pop.....back now?
Might get a huge uptick....LUDP trading code....volitilty
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Aug 20, 2024 10:32am
CVKD.... 15 : 1 RS effective this a.m
On watch for a dramatic increase in share price....maybe ; ) Currently at $6.20 on 26K shs traded...low vol
(9)
•••
MikeTester
X
Post by
MikeTester
on Aug 02, 2024 10:23am
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD): A Promising Antic
https://beyondspx.com/2024/07/31/cadrenal-therapeutics-inc-nasdaqcvkd-a-promising-anticoagulant-candidate-targeting-unmet-needs/
Prev
1
2
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Introducing the NEW DealRoom: Your Gateway to Capital-Raising Investments
Are PGM mining stocks an attractive area for your next portfolio allocation?
ReGen III Appoints New CEO and President to Accelerate Commercial and Strategic Opportunities